One of the most critical topics to address in health care today is the mental health and well-being of physicians and other ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...